These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30587493)

  • 1. Imatinib is still recommended for frontline therapy for CML.
    Hantel A; Larson RA
    Blood Adv; 2018 Dec; 2(24):3648-3652. PubMed ID: 30587493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 3. Bosutinib more effective than imatinib in CML.
    Gourd E
    Lancet Oncol; 2017 Dec; 18(12):e716. PubMed ID: 29129440
    [No Abstract]   [Full Text] [Related]  

  • 4. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
    Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
    Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
    [No Abstract]   [Full Text] [Related]  

  • 6. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
    Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
    Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
    Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
    In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
    Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
    Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
    Cai Y; Liu C; Guo Y; Chen X; Zhang L; Chen Y; Zou Y; Yang W; Zhu X
    Int J Hematol; 2021 Mar; 113(3):413-421. PubMed ID: 33386594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Myeloid Leukemia--Prognostic Value of Mutations.
    Kaleem B; Shahab S; Ahmed N; Shamsi TS
    Asian Pac J Cancer Prev; 2015; 16(17):7415-23. PubMed ID: 26625737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.